Company Encyclopedia
View More
name
Qianhong Bio-pharma
002550.SZ
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase. It also provides low molecular weight heparin, compound digestive enzyme preparations, and health products. In addition, the company exports its products.
3.159 T
002550.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking34/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE16.45%A
    • Profit Margin28.02%A
    • Gross Margin61.13%A
  • Growth ScoreC
    • Revenue YoY-1.43%D
    • Net Profit YoY46.35%B
    • Total Assets YoY9.17%B
    • Net Assets YoY11.06%B
  • Cash ScoreC
    • Cash Flow Margin356.94%C
    • OCF YoY-1.43%D
  • Operating ScoreC
    • Turnover0.53C
  • Debt ScoreA
    • Gearing Ratio8.48%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Qianhong Bio-pharma: The net profit for the third quarter was 125 million yuan, a year-on-year decrease of 1.28%

    Qianhong Bio-pharma announced that its revenue for the third quarter was 353 million yuan, a year-on-year increase of 0.35%; net profit was 125 million yuan, a year-on-year decrease of 1.28%. Revenue for the first three quarters was 1.215 billion yuan, a year-on-year increase of 0.61%; net profit was 383 million yuan, a year-on-year increase of 23.79%

    Zhitong·
    SZ
    002550
    +0.25%
    Zhitong·
    SZ
    002550
    +0.25%

    Qianhong Bio-pharma: Warned for failing to disclose and halt trading in a timely manner when the shareholding ratio reached the 25% threshold

    Qianhong Bio-pharma announced that shareholder Wang Ke increased his holdings in the company by 9.6 million shares through block trading on June 11, 2025, raising his ownership ratio from 24.91% to 25.66%. Due to the failure to timely disclose the situation when the ownership ratio reached 25%, the Jiangsu Securities Regulatory Bureau issued a warning letter to Wang Ke on September 11, 2025, and required him to submit a written report within 10 working days

    Zhitong·
    SZ
    002550
    +0.25%
    Zhitong·
    SZ
    002550
    +0.25%

    Qianhong Bio-pharma released its performance for the first half of the year, with a net profit attributable to the parent company of 258 million yuan, an increase of 41.17%

    According to the Zhitong Finance APP, Qianhong Bio-pharma released its semi-annual report for 2025, showing an operating income of 862 million yuan, a year-on-year increase of 0.72%. The net profit attributable to shareholders of the listed company was 258 million yuan, a year-on-year increase of 41.17%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 199 million yuan, a year-on-year increase of 10.71%. The basic earnings per share were 0.2065 yuan

    Zhitong·
    SZ
    002550
    +0.25%
    Zhitong·
    SZ
    002550
    +0.25%

    Qianhong Bio-pharma shareholder Zhao Gang and his concerted actors plan to reduce their holdings by no more than 20.9 million shares

    According to the Zhitong Finance APP, Qianhong Bio-pharma announced that the company's shareholder Mr. Zhao Gang and his concerted parties, including Jianxin Fund - Zhao Renyi - Jianxin Xinxiang No. 1 Single Asset Management Plan, plan to reduce their holdings in the company by no more than 20.9 million shares (accounting for 1.63% of the company's current total share capital and 1.67% of the total share capital excluding the shares held in the repurchase special account) through centralized bidding and block trading within three months after the announcement date, starting from 15 trading days after the disclosure of this announcement

    Zhitong·
    SZ
    002550
    +0.25%
    Zhitong·
    SZ
    002550
    +0.25%

    The concept of innovative drugs fluctuates and rebounds, ALK hits the limit and reaches a historical high

    In the afternoon, the innovative drug concept fluctuated and rebounded, with the high-profile stock ALK hitting the daily limit and reaching a new historical high. Previously, Han Commercial Group had two consecutive limit-ups, while Jincheng Pharmaceutical, Olymvax Biopharmaceuticals, and Jiankai Technology rose over 10%. Borui Pharmaceutical, Konruns, Qianhong Bio-pharma, and Jibeier also followed suit

    Zhitong·
    SZ
    002940
    -1.44%
    SZ
    002550
    +0.25%
    SH
    688319
    -2.14%
    Zhitong·
    SZ
    002940
    -1.44%
    SZ
    002550
    +0.25%
    SH
    688319
    -2.14%
    © 2025 Longbridge｜Disclaimer